Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption
Windtree Therapeutics (NASDAQ:WINT) has announced significant reductions in its preferred stock shares outstanding through conversion and redemption. The company achieved a 99.3% reduction in Series C Preferred Stock to just 19 shares and a 68.5% reduction in Series D Preferred Stock to 1,161 shares between April 15 and July 25, 2025.
The announcement comes alongside updates on Windtree's crypto treasury strategy, including a $60 million investment agreement with Build and Build Corp, with potential follow-on subscriptions of up to $140 million. The company has also secured commitments for up to $700 million for BNB acquisitions. Notably, BNB coin has appreciated by over 17% since the initial announcement of the crypto treasury agreement.
Investors redeemed approximately $2.3 million worth of preferred series C and D shares, which could have been converted into approximately 7.7 common shares, effectively limiting future dilution.
Windtree Therapeutics (NASDAQ:WINT) ha annunciato una significativa riduzione delle azioni privilegiate in circolazione tramite conversione e riscatto. Tra il 15 aprile e il 25 luglio 2025, la societ脿 ha ottenuto una riduzione del 99,3% delle azioni privilegiate di Serie C, portandole a sole 19 azioni, e una riduzione del 68,5% delle azioni privilegiate di Serie D a 1.161 azioni.
L'annuncio 猫 accompagnato da aggiornamenti sulla strategia di tesoreria crypto di Windtree, tra cui un accordo di investimento da 60 milioni di dollari con Build and Build Corp, con potenziali sottoscrizioni aggiuntive fino a 140 milioni di dollari. La societ脿 ha inoltre assicurato impegni per acquisizioni di BNB fino a 700 milioni di dollari. Di rilievo, il valore della moneta BNB 猫 aumentato di oltre il 17% dall'annuncio iniziale dell'accordo sulla tesoreria crypto.
Gli investitori hanno riscattato azioni privilegiate delle serie C e D per un valore di circa 2,3 milioni di dollari, che avrebbero potuto essere convertite in circa 7,7 azioni ordinarie, limitando cos矛 la diluizione futura.
Windtree Therapeutics (NASDAQ:WINT) ha anunciado reducciones significativas en sus acciones preferentes en circulaci贸n mediante conversi贸n y redenci贸n. Entre el 15 de abril y el 25 de julio de 2025, la compa帽铆a logr贸 una reducci贸n del 99,3% en las acciones preferentes Serie C a solo 19 acciones y una reducci贸n del 68,5% en las acciones preferentes Serie D a 1.161 acciones.
El anuncio se produce junto con actualizaciones sobre la estrategia de tesorer铆a cripto de Windtree, incluyendo un acuerdo de inversi贸n de 60 millones de d贸lares con Build and Build Corp, con posibles suscripciones adicionales de hasta 140 millones de d贸lares. La empresa tambi茅n ha asegurado compromisos para adquisiciones de BNB por hasta 700 millones de d贸lares. Cabe destacar que la moneda BNB ha apreciado m谩s del 17% desde el anuncio inicial del acuerdo de tesorer铆a cripto.
Los inversores redimieron aproximadamente 2,3 millones de d贸lares en acciones preferentes de las series C y D, que podr铆an haberse convertido en aproximadamente 7,7 acciones comunes, limitando efectivamente la diluci贸n futura.
Windtree Therapeutics (NASDAQ:WINT)電� 鞝勴櫂 氚� 靸來櫂鞚� 韱淀暣 鞖办劆欤� 氚滍枆 欤检嫕 靾橂ゼ 雽�韽� 欷勳榾雼り碃 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 2025雲� 4鞗� 15鞚茧秬韯� 7鞗� 25鞚� 靷澊鞐� 鞁滊Μ歃� C 鞖办劆欤茧ゼ 99.3% 臧愳唽鞁滌紲 雼� 19欤茧 欷勳榾鞙茧┌, 鞁滊Μ歃� D 鞖办劆欤茧弰 68.5% 臧愳唽鞁滌紲 1,161欤茧 欷勳榾鞀惦媹雼�.
鞚措矆 氚滍憸電� Windtree鞚� 鞎旐樃頇旐彁 鞛愳偘 鞖挫毄 鞝勲灥鞐� 雽�頃� 鞐呺嵃鞚错姼鞕� 頃粯 鞚措（鞏挫鞙茧┌, Build and Build Corp鞕� 6,000毵� 雼煬 韴瀽 瓿勳暯鞚� 觳搓舶頄堦碃, 斓滊寑 1鞏� 4,000毵� 雼煬鞚� 於旉皜 甑弲 臧�電レ劚霃� 韽暔霅橃柎 鞛堨姷雼堧嫟. 霕愴暅 須岇偓電� BNB 毵れ瀰鞚� 鞙勴暣 斓滊寑 7鞏� 雼煬鞚� 鞎届啀旮堨暋霃� 頇曤炒頄堨姷雼堧嫟. 韸鬼瀳 BNB 旖旍澑鞚� 鞎旐樃頇旐彁 鞛愳偘 鞖挫毄 瓿勳暯 齑堦赴 氚滍憸 鞚错泟 17% 鞚挫儊 靸侅姽頄堨姷雼堧嫟.
韴瀽鞛愲摛鞚� 鞎� 230毵� 雼煬 靸侂嫻鞚� 鞁滊Μ歃� C 氚� D 鞖办劆欤茧ゼ 靸來櫂頄堨溂氅�, 鞚措姅 鞎� 7.7欤� 氤错喌欤茧 鞝勴櫂霅� 靾� 鞛堨棃雿� 攴滊搿�, 頄ロ泟 頋劃鞚� 須臣鞝侅溂搿� 鞝滍暅頄堨姷雼堧嫟.
Windtree Therapeutics (NASDAQ:WINT) a annonc茅 d'importantes r茅ductions de ses actions privil茅gi茅es en circulation par conversion et rachat. Entre le 15 avril et le 25 juillet 2025, la soci茅t茅 a r茅alis茅 une r茅duction de 99,3 % des actions privil茅gi茅es de la s茅rie C 脿 seulement 19 actions, ainsi qu'une r茅duction de 68,5 % des actions privil茅gi茅es de la s茅rie D 脿 1 161 actions.
Cette annonce s'accompagne de mises 脿 jour concernant la strat茅gie de tr茅sorerie crypto de Windtree, incluant un accord d'investissement de 60 millions de dollars avec Build and Build Corp, avec des souscriptions potentielles suppl茅mentaires allant jusqu'脿 140 millions de dollars. La soci茅t茅 a 茅galement obtenu des engagements pour des acquisitions de BNB allant jusqu'脿 700 millions de dollars. Notamment, la valeur de la cryptomonnaie BNB a augment茅 de plus de 17 % depuis l'annonce initiale de l'accord de tr茅sorerie crypto.
Les investisseurs ont rachet茅 environ 2,3 millions de dollars d'actions privil茅gi茅es des s茅ries C et D, qui auraient pu 锚tre converties en environ 7,7 actions ordinaires, limitant ainsi efficacement la dilution future.
Windtree Therapeutics (NASDAQ:WINT) hat bedeutende Reduzierungen der ausstehenden Vorzugsaktien durch Umwandlung und R眉ckkauf bekannt gegeben. Das Unternehmen erreichte zwischen dem 15. April und dem 25. Juli 2025 eine Reduzierung der Serie-C-Vorzugsaktien um 99,3 % auf nur 19 Aktien und eine Reduzierung der Serie-D-Vorzugsaktien um 68,5 % auf 1.161 Aktien.
Die Ank眉ndigung erfolgt zusammen mit Updates zur Krypto-Treasury-Strategie von Windtree, darunter eine Investitionsvereinbarung 眉ber 60 Millionen US-Dollar mit Build and Build Corp, mit potenziellen Folgezeichnungen von bis zu 140 Millionen US-Dollar. Das Unternehmen hat zudem Zusagen f眉r BNB-Akquisitionen in H枚he von bis zu 700 Millionen US-Dollar gesichert. Bemerkenswert ist, dass die BNB-M眉nze seit der ersten Ank眉ndigung der Krypto-Treasury-Vereinbarung um 眉ber 17 % im Wert gestiegen ist.
Investoren haben Vorzugsaktien der Serien C und D im Wert von etwa 2,3 Millionen US-Dollar eingel枚st, die in etwa 7,7 Stammaktien h盲tten umgewandelt werden k枚nnen, was eine zuk眉nftige Verw盲sserung effektiv begrenzt.
- 99.3% reduction in Series C Preferred Stock and 68.5% reduction in Series D Preferred Stock, limiting future dilution
- $60 million investment agreement with Build and Build Corp, with up to $140 million in follow-on subscriptions
- 17% appreciation in BNB coin value since treasury agreement announcement
- Up to $700 million committed to BNB acquisitions
- Reduction of potential dilution by redemption of $2.3 million in preferred shares
- Crypto treasury strategy and investments subject to stockholder approval
- Significant exposure to cryptocurrency market volatility through BNB strategy
Insights
Windtree's significant reduction of preferred shares reduces future dilution risk while pursuing controversial crypto treasury strategy.
Windtree Therapeutics has executed a substantial restructuring of its capital structure by dramatically reducing its outstanding preferred stock. The company has eliminated 99.3% of Series C and 68.5% of Series D preferred shares through redemptions and conversions. Only 19 Series C and 1,161 Series D shares remain outstanding as of July 25, 2025.
The financial implications are significant. Investors chose to redeem approximately
Simultaneously, Windtree is pursuing an unconventional treasury strategy involving cryptocurrency. The company has announced a
This dual approach鈥攔educing potential dilution while pivoting toward a crypto treasury strategy鈥攔epresents a highly unusual strategic direction for a biotechnology company. The management appears to be diversifying beyond traditional biotech activities, as evidenced by the reference to "diversifying its portfolio through strategic initiatives." This shift raises questions about the company's core focus and risk profile going forward.
Investors choose to redeem or convert the majority of Series C and Series D Preferred
BNB coin has appreciated over
WARRINGTON, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (鈥淲indtree鈥� or the 鈥淐ompany鈥�) (NasdaqCM: WINT), a biotechnology company diversifying its portfolio through strategic initiatives, today announced large reductions in outstanding shares of its preferred series C and D shares. Only 19 preferred series C shares remain.
The majority of the Company鈥檚 Series C Convertible Preferred Stock (鈥淪eries C Preferred Stock鈥�) and Series D Convertible Preferred Stock (鈥淪eries D Preferred Stock鈥�) has been converted or redeemed. 19 shares of Series C Preferred Stock and 1,161 shares of Series D Preferred Stock remain outstanding as of July 25, 2025, representing a
The Company previously announced its plan to launch a BNB crypto treasury strategy with an agreement for
鈥淲indtree has greatly reduced the number of outstanding shares of its Series C Preferred Stock and Series D Preferred Stock, limiting future dilution from preferred conversion vs redemption,鈥� said Jed Latkin, Chief Executive Officer of Windtree. 鈥淚nvestors redeemed ~
See our public filings at . This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is a diversified company with several divisions, including a cryptocurrency treasury strategy and two promising therapeutic pipelines for which the Company is actively seeking long-term development partners.
About Build and Build Corp
Build and Build Corp is a dynamic company established by Patrick Horsman, Joshua Kruger, and Johnathan Pasch, who together bring over 43 years of expertise in hedge funds and digital asset management. The company is backed by prominent investors, including Off The Chain Capital, Kraken, Galaxy, and Silvermine, supporting its mission to deliver innovative solutions in the financial and digital asset sectors.
Forward-Looking Statements
The Company may, in some cases, use terms such as 鈥減redicts,鈥� 鈥渂elieves,鈥� 鈥減otential,鈥� 鈥減roposed,鈥� 鈥渃ontinue,鈥� 鈥渆stimates,鈥� 鈥渁nticipates,鈥� 鈥渆xpects,鈥� 鈥減lans,鈥� 鈥渋ntends,鈥� 鈥渕ay,鈥� 鈥渃ould,鈥� 鈥渕ight,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from the Company鈥檚 current expectations. Examples of such risks and uncertainties include, among other things: risks related to the Company鈥檚 ability to manage costs and execute on its operational and budget plans; risks related to the regulatory environment for cryptocurrency transactions; and the Company鈥檚 ability to develop and maintain its BNB Crypto Treasury Strategy. These and other risks are described in the Company鈥檚 periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact Information:
Eric Curtis
[email protected]
FAQ
What is the current status of Windtree Therapeutics (WINT) preferred stock shares?
How much investment has Windtree Therapeutics secured for its crypto treasury strategy?
What is the value of preferred shares redeemed by WINT investors?
How has the BNB coin performed since Windtree's crypto treasury announcement?
What approvals are needed for Windtree's crypto treasury strategy?
